In 2017, Remedy sold the CIRARA program to Biogen (a multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide) for $120 million upfront, plus potential milestone and royalty payments that, in total, could be several hundred million dollars or more.
Biogen began enrolling patients into a large, 680-patient phase 3 study of subjects with large hemispheric infarctions in 2018. To quote Biogen, “BIIB093 (CIRARA) has the potential to be the first major innovation in stroke in over 20 years.”
In 2019 Biogen started a second trial of CIRARA, a 160-patient phase 2 study in brain contusion. As Biogen has noted, “We believe that the shared pathophysiologic features of LHI and brain contusion exemplify the interconnectivity of neuroscience that we are leveraging as we continue to increase the depth and breadth of our pipeline.”